i
Interim Statement Regarding Potential Fetal Harm from Exposure to Dolutegravir – Implications for HIV Post-exposure Prophylaxis (PEP)
-
05/23/2018
Details:
-
Corporate Authors:
-
Description:Guidance to providers regarding the use of Dolutegravir. A preliminary unscheduled analysis of data from an ongoing NIH-funded observational study in Botswana suggests that an increased risk of neural tube defects was associated with exposure to antiretroviral (ARV) regimens that include dolutegravir (DTG) at conception.
-
Subjects:
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: